



PPL/CS/SE/07/2014
14th February, 2014

To
BSE Limited
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001
Kind Attn.: Mr. Gopal K. Iyer

The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai 400 051
Kind Attn.: Mr. Hari K.

Sub.: Corporate Announcement for the Outcome of the meeting of the Board of Directors of the Company held on 14th day of February, 2014.

Dear Sir,

This has in reference with our notice dated 6th February, 2014 regarding holding a meeting of the Board of Directors of the Company on Friday, the 14th February, 2014.

We would like to inform that the Board of Directors of the Company at their meeting held on today, i.e., Friday, the 14th February, 2014, inter-alia, approved and take on record the Un-audited Financial Results of the Company for the quarter and twelve months ended 31st December, 2013. The aforesaid Un-audited results have also reviewed by the Auditors of the Company.

Please find herewith the enclosed copy of the approved un-audited financial results of the Company for the quarter ended 31st December, 2013 and the Limited Review Report of the Auditor.

You are requested to please consider and take on record the above for your reference and records.

Thanking You

Yours Sincerely,
For **PLETHICO PHARMACEUTICALS LIMITED**

KHUSHBOO KOTHARI
COMPANY SECRETARY



Encl.: - As above

PLETHICO PHARMACEUTICALS LIMITED


Regd. Office : A.B. Road, Manglia - 453 771, Dist. - Indore (M.P.) Tel.: +91-731-2806275, +91-731-2806271
Admn. Office : 37, Industrial Estate, Pologround, Indore - 452 015 (M.P.) Tel.: +91-731-2422881/84

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND TWELVE MONTHS ENDED 31ST DECEMBER, 2013

(Rs in Lakh, except share data, per share data and unless otherwise stated)

Sr. No.	Particulars	Standalone Financials					Consolidated Financials				
		3 Month Ended			12 Month Ended (Refer to Note 11)	Year Ended	3 Month Ended			12 Month Ended (Refer to Note 11)	Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012
		(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations										
a)	Net Sales/Income from Operations	7590.80	10547.23	13806.67	46602.26	47505.97	36404.07	43912.37	47163.02	174678.27	163154.12
b)	Other Operating Income	38.97	745.67	556.82	3978.00	2138.36	33.60	745.67	376.15	3992.61	2215.26
	Total Income from operations (1+2)	7629.77	11292.90	14363.50	50580.26	49644.34	36437.67	44658.05	47539.17	178670.88	165369.38
2	Expenses										
a)	Cost of Material Consumed	2724.02	4481.40	7550.78	16956.94	25155.50	1705.90	8299.04	10647.50	30930.55	37998.20
b)	Purchase of Finished goods	2853.48	3401.62	7026.23	20513.91	15311.45	15265.82	24901.35	16147.98	78844.79	58941.28
c)	(Increase) / Decrease in Stock in trade & work in progress	234.30	(38.45)	(88.35)	445.62	(93.14)	2451.48	(2160.49)	8212.44	(2156.75)	(1251.16)
d)	Employees Cost	585.62	722.55	239.08	2790.01	2891.51	4516.15	2996.70	2908.14	12915.82	11891.54
e)	Depreciation/Amortization	205.92	207.26	222.66	831.00	880.24	2742.19	723.17	386.28	4844.28	1772.98
f)	Other Expenditure	898.71	924.59	2175.72	3992.98	4980.88	2525.60	5209.26	13611.33	31095.32	39777.03
	Total Expenses	7502.04	9698.98	17126.11	45530.46	49126.43	29207.14	39969.02	51913.68	156474.00	149129.88
3	Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)	127.73	1593.92	(2762.62)	5049.80	517.90	7230.53	4689.03	(4374.51)	22196.88	16239.50
4	Other income	(4.37)	21.20	15.67	31.95	20.06	(4.37)	21.20	15.67	149.98	20.06
5	Profit (+) / Loss (-) from Ordinary Activities before finance costs and exceptional items (3+4)	123.36	1615.12	(2746.95)	5081.75	537.96	7226.16	4710.23	(4358.84)	22346.86	16259.56
6	Finance Costs	1096.77	1368.37	1467.48	5064.92	4992.62	2894.43	2265.01	1774.72	10230.61	6143.22
7	Profit / Loss from Ordinary Activities after finance costs but before exceptional items (5+6)	(973.41)	246.75	(4214.43)	16.83	(4454.66)	4331.73	2445.22	(6133.56)	12116.25	10116.34
8	Exceptional items	-	-	-	-	3749.48	-	-	(2938.00)	-	811.48
9	Profit / Loss from Ordinary Activities before tax (7-8)	(973.41)	246.75	(4214.43)	16.83	(705.18)	4331.73	2445.22	(9071.56)	12116.25	10927.82
10	Tax expense	(293.93)	83.87	(500.00)	42.65	84.05	(75.00)	348.24	(1547.87)	(150.90)	779.03
11	Net Profit / Loss from Ordinary Activities after tax (9-10)	(679.48)	162.88	(3714.43)	(25.82)	(789.23)	4406.73	2096.97	(7523.68)	12267.14	10148.80
12	Extra-Ordinary Items (net of tax expense)	-	-	-	-	-	-	-	-	-	-
13	Net Profit / Loss for the period (11+12)	(679.48)	162.88	(3714.43)	(25.82)	(789.23)	4406.73	2096.97	(7523.68)	12267.14	10148.80
14	Share of profit / (Loss) of associates	-	-	-	-	-	-	-	-	-	-
15	Minority interest	-	-	-	-	-	-	-	-	-	-
16	Net Profit / Loss after taxes, minority interest and share of profit / (Loss) of associates (13+14+15)	(679.48)	162.88	(3714.43)	(25.82)	(789.23)	4406.73	2096.97	(7523.68)	12267.14	10148.80
17	Paid-up equity share capital (Nominal Value - Rs. 10/- each)	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67	3406.67
18	Reserves excluding Revaluation reserves as per balance sheet of previous accounting year	-	-	-	51303.39	51329.21	-	-	-	165368.01	133290.26
19.i	Earning/(loss) per share (before Extra-Ordinary items) (not to be annualized) (Rs.)										
	Basic	(1.99)	0.48	(10.90)	(0.08)	(2.32)	12.94	6.16	(22.09)	36.01	29.79
	Diluted	(1.99)	0.48	(10.90)	(0.08)	(2.32)	12.94	6.16	(22.09)	36.01	29.79
19.ii	Earning/(loss) per share (After-Ordinary items) (not to be annualized) (Rs.)										
	Basic	(1.99)	0.48	(10.90)	(0.08)	(2.32)	12.94	6.16	(22.09)	36.01	29.79
	Diluted	(1.99)	0.48	(10.90)	(0.08)	(2.32)	12.94	6.16	(22.09)	36.01	29.79
A	PARTICULARS OF SHAREHOLDING										
1	Public Shareholding										
a)	Number of equity shares	7855737	7855622	5892622	7855737	5892622	7855737	7855622	5892622	7855737	5892622
b)	Percentage of Shareholding.	23.06%	23.06%	17.30%	23.06%	17.30%	23.06%	23.06%	17.30%	23.06%	17.30%
2	Promoter and Promoter Group Shareholding :										
a)	Pledged/Encumbered										
-	Number of shares	22731885	22732000	27564950	22731885	27564950	22731885	22732000	27564950	22731885	27564950
-	Percentage of Shares (as a % of total shareholding of promoter and promoter group)	86.73%	86.73%	97.84%	86.73%	97.84%	86.73%	86.73%	97.84%	86.73%	97.84%
-	Percentage of shares (as a % of the total share capital of the Company)	66.73%	66.73%	80.91%	66.73%	80.91%	66.73%	66.73%	80.91%	66.73%	80.91%
b)	Non-encumbered										
-	Number of shares	3479045	3479045	609095	3479045	609095	3479045	3479045	609095	3479045	609095
-	Percentage of Shares (as a % of total shareholding of promoter and promoter group)	13.27%	13.27%	2.16%	13.27%	2.16%	13.27%	13.27%	2.16%	13.27%	2.16%
-	Percentage of shares (as a % of the total share capital of the Company)	10.21%	10.21%	1.79%	10.21%	1.79%	10.21%	10.21%	1.79%	10.21%	1.79%

B	INVESTOR COMPLAINTS	3 Month Ended
		31.12.2013
	Pending at the beginning of the quarter	Nil
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	Nil



Note :-

1. Statement of Assets and Liabilities are given below:-

Disclosure of Balance Sheet Items as per Clause 41 (V) (h) of the Listing Agreement for the Half Year Ended 31st December, 2013

Sr. No	Particulars	Standalone		Consolidated	
		As at		As at	
		31.12.2013 Unaudited (Refer to Note 11)	31.12.2012 Audited	31.12.2013 Unaudited (Refer to Note 11)	31.12.2012 Audited
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	a) Share Capital	3406.67	3406.67	3406.67	3406.67
	b) Reserves and Surplus	51303.39	51329.21	165368.01	133290.26
	c) Money received against share warrants	-	-	-	-
		54710.05	54735.87	168774.68	136696.93
2	Share application money pending allotment	-	-	-	-
3	Minority Interest	-	-	-	-
4	Non-current liabilities				
	a) Long-term borrowings	5410.32	13020.87	46795.64	25584.47
	b) Deferred tax liabilities (net)	1719.42	1679.98	1796.15	-
	c) Other long term liabilities	1983.74	1257.52	2203.65	1257.52
	d) long term provisions	-	-	-	-
		9113.48	16958.37	50795.43	26841.99
5	Current liabilities				
	a) Short-term borrowings	15177.37	21893.86	15238.93	22076.46
	b) Trade payable	1891.93	2288.20	9970.95	6398.80
	c) Other current liabilities	79646.85	69267.12	81271.89	74791.47
	d) Short term provisions	6256.05	6276.03	6320.31	6359.69
		102972.20	99725.21	112802.08	109626.42
	TOTAL-EQUITY AND LIABILITIES	166795.74	170419.45	332372.20	273165.34
B	ASSETS				
1	Non-current assets				
	a) Tangible Assets	12001.91	12821.23	12858.88	13215.53
	b) Intangible Assets	-	-	58355.79	41996.86
	b) Goodwill on consolidation	-	-	30510.24	26997.36
	c) Non-current investments	80655.91	80655.91	19892.39	19895.99
	d) Deferred tax assets (Net)	-	-	0.00	895.42
	e) Long term loans and advances	-	-	1943.21	78.50
	f) Other non-current assets	-	-	23158.80	-
		92657.81	93477.14	146719.30	103079.66
2	Current assets				
	a) Current investments	-	-	-	-
	b) Inventories	1761.24	2253.69	22358.95	18949.64
	c) Trade Receivables	66017.43	67295.17	121659.71	122379.79
	d) Cash and cash equivalents	1833.66	2604.38	3886.19	3156.85
	e) Short term loans and advances	4525.60	4789.07	37260.72	25436.83
	f) Other current assets	-	-	487.33	162.56
		74137.93	76942.31	185652.90	170085.68
	TOTAL ASSETS	166795.74	170419.45	332372.20	273165.34

2. The above Unaudited Financial Results for the quarter and twelve months ended 31st December, 2013 were approved at the meeting of the Board of Directors held on 14th February, 2014, after being approved and recommended by the Audit Committee.

3. The Statutory Auditors have carried out a limited audit review of the results for the quarter ended on 31st December, 2013.

4. The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.

5. The EPS has been computed in accordance with the accounting standards (AS-20) issued by the ICAI.

6. Figures of the previous quarter / year wherever necessary have been regrouped and reclassified to confirm to those of the current quarter.

7. The cost of Packing materials has been included in Material cost, whereas Directors' remuneration has been included in the employees cost.

8. The consolidated financial results comprise unaudited results of its wholly owned subsidiary Plethico International Ltd and Plethico Global Holdings B.V., Netherlands having different step-down subsidiaries particularly Plethico US Holding KFT Hungary, Natrol Inc., USA. and Natrol Global UAE., The financial results of subsidiary companies have been regrouped and / or rearranged wherever necessary due to Indian GAPP audit conducted.

9. The amount payable on Foreign Currency Convertible Bonds (FCCBs) issued by the Company which was matured on 23rd October, 2012, has been disputed by the Company and legal proceedings are pending in Courts filed by and against the Company.

10. The Company has not provided for contingent liabilities, including contingent tax liabilities in its books.

11. The Board of Directors vide resolution dated 24th January, 2014 has approved the change of financial year of the company from January-December to April-March, effective from 01st April 2014. In view of this, the current financial year will be for a period of 15 month i.e. 01st January 2013 to 31st March, 2014.

Date : 14.02.2014

Place : Mumbai



For PLETHICO PHARMACEUTICALS LIMITED

SHASHIKANT PATEL
CHAIRMAN CUM MANAGING DIRECTOR

N. P. GANDHI & CO.

CHARTERED ACCOUNTANTS

10, Radha Chambers, Level 3, Telli Park Lane, Andheri (East), Mumbai 400 069 Tel.: 2683 9105 Email: nilesh@npgandhico.net


Review Report to the Members of Plethico Pharmaceuticals Limited

We have reviewed the accompanying statement of un-audited financial results of **Plethico Pharmaceuticals Limited** for the period ended 31st December, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N.P.Gandhi & Co.
Chartered Accountants
FRNo: 116574W



Nilesh Gandhi
Proprietor
M.No. 44294



14th February, 2014